| Phase 110 trials |
|
Phase 1
|
NCT06710223 |
Jan 2025 → Jun 2027 expected |
hepatocellular carcinoma |
University of California, San Diego |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05607953 |
Mar 2023 → Sep 2027 expected |
pancreatic adenocarcinoma |
TriSalus Life Sciences, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04935229 |
Aug 2021 → Jul 2024 |
uveal melanoma |
TriSalus Life Sciences, Inc. |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 1
|
NCT04050085 |
Aug 2019 → Dec 2021 |
pancreatic adenocarcinoma |
University of California, Davis |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03831295 |
Mar 2019 → Oct 2021 |
metastatic malignant neoplasm |
Ronald Levy |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03410901 |
Apr 2018 → Oct 2024 |
chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma |
Ronald Levy |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02731742 |
Jun 2016 → Jan 2018 |
neoplasm |
Merck Sharp & Dohme LLC |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 1
|
NCT01745354 |
Aug 2012 → Nov 2014 |
Hodgkins lymphoma, non-Hodgkin lymphoma |
Robert Lowsky |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 1
|
NCT00823862 |
Oct 2008 → Dec 2009 |
chronic hepatitis C virus infection |
Dynavax Technologies Corporation |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00599001 |
Jan → Mar 2008 |
— |
Dynavax Technologies Corporation |
Completed
|
No outcome recorded
|
| Phase 1/26 trials |
|
Phase 1/2
|
NCT05220722 |
Mar 2022 → Jul 2024 |
hepatocellular carcinoma, intrahepatic cholangiocarcinoma |
TriSalus Life Sciences, Inc. |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 1/2
|
NCT03322384 |
Jan 2018 → Feb 2020 |
cancer, lymphoma |
University of California, Davis |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02927964 |
Nov 2016 → May 2023 |
follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma |
Robert Lowsky |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02521870 |
Sep 2015 → Apr 2020 |
head and neck cancer, metastatic melanoma |
Dynavax Technologies Corporation |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 1/2
|
NCT02266147 |
Oct 2014 → Apr 2017 |
B-cell neoplasm |
Dynavax Technologies Corporation |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT02254772 |
Sep 2014 → Nov 2016 |
MALT lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma |
Robert Lowsky |
Completed
|
No outcome recorded
|
| Phase 22 trials · 1 missed |
|
Phase 2
|
NCT02014376 |
Jan → Jun 2014 |
epidermolysis bullosa |
Scioderm, Inc. |
Completed
|
Missed primary
|
|
Phase 2
|
NCT01042379 |
Mar 2010 → Dec 2030 expected |
HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 |
QuantumLeap Healthcare Collaborative |
Recruiting
|
No outcome recorded
|